Assertio Holdings, Inc. (NASDAQ:ASRT) Director Heather L. Mason Sells 89,286 Shares of Stock

Assertio Holdings, Inc. (NASDAQ:ASRT – Get Rating) Director Heather L. Mason sold 89,286 shares of the business’s stock in a transaction that occurred on Friday, May 19th. The stock was sold at an average price of $7.30, for a total transaction of $651,787.80. Following the sale, the director now owns 187,650 shares of the company’s stock, valued at $1,369,845. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Assertio Price Performance

Shares of ASRT stock opened at $7.04 on Tuesday. The company has a market capitalization of $391.85 million, a PE ratio of 4.66, a price-to-earnings-growth ratio of 1.56 and a beta of 1.39. The firm has a fifty day simple moving average of $6.22 and a 200-day simple moving average of $4.84. The company has a current ratio of 1.46, a quick ratio of 1.29 and a debt-to-equity ratio of 0.15. Assertio Holdings, Inc. has a twelve month low of $2.07 and a twelve month high of $8.01.

Assertio (NASDAQ:ASRT – Get Rating) last posted its quarterly earnings data on Wednesday, March 8th. The company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $1.11. Assertio had a net margin of 59.86% and a return on equity of 52.50%. The firm had revenue of $50.35 million for the quarter, compared to the consensus estimate of $49.57 million. Equities research analysts anticipate that Assertio Holdings, Inc. will post 0.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

ASRT has been the subject of several research reports. StockNews.com downgraded shares of Assertio from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Lake Street Capital boosted their price objective on shares of Assertio from $8.00 to $9.00 in a research note on Wednesday, May 10th. TheStreet upgraded shares of Assertio from a “c-” rating to a “b-” rating in a research note on Wednesday, March 29th. Finally, BWS Financial upped their target price on shares of Assertio from $8.00 to $10.00 in a research note on Wednesday, May 10th. One analyst has rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $9.50.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in Assertio by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,111,276 shares of the company’s stock valued at $4,792,000 after acquiring an additional 5,400 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Assertio by 143.2% during the 1st quarter. Renaissance Technologies LLC now owns 2,013,135 shares of the company’s stock valued at $12,824,000 after acquiring an additional 1,185,400 shares during the last quarter. Acadian Asset Management LLC boosted its stake in Assertio by 0.7% during the 1st quarter. Acadian Asset Management LLC now owns 1,154,529 shares of the company’s stock valued at $7,350,000 after acquiring an additional 8,316 shares during the last quarter. BlackRock Inc. boosted its stake in Assertio by 3.4% during the 1st quarter. BlackRock Inc. now owns 964,053 shares of the company’s stock valued at $6,141,000 after acquiring an additional 31,288 shares during the last quarter. Finally, First Eagle Investment Management LLC boosted its stake in Assertio by 37.6% during the 4th quarter. First Eagle Investment Management LLC now owns 688,075 shares of the company’s stock valued at $2,959,000 after acquiring an additional 188,076 shares during the last quarter. 33.31% of the stock is currently owned by institutional investors.

Assertio Company Profile

(Get Rating)

Assertio Holdings, Inc engages in the provision of commercial pharmaceutical products. Its commercial portfolio of branded products focuses on the following areas: neurology, hospital, and pain and inflammation. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.